KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Change in Intangibles (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Change in Intangibles data on record, last reported at $3.0 million in Q4 2025.

  • For Q4 2025, Change in Intangibles rose 400.0% year-over-year to $3.0 million; the TTM value through Dec 2025 reached $15.5 million, up 5.9%, while the annual FY2025 figure was $15.5 million, 5.9% up from the prior year.
  • Change in Intangibles reached $3.0 million in Q4 2025 per AMRX's latest filing, down from $7.4 million in the prior quarter.
  • Across five years, Change in Intangibles topped out at $31.8 million in Q3 2022 and bottomed at $338000.0 in Q1 2023.
  • Average Change in Intangibles over 5 years is $6.0 million, with a median of $2.1 million recorded in 2021.
  • The widest YoY moves for Change in Intangibles: up 2769.82% in 2024, down 96.98% in 2024.
  • A 5-year view of Change in Intangibles shows it stood at $1.2 million in 2021, then skyrocketed by 2550.0% to $31.8 million in 2022, then tumbled by 37.42% to $19.9 million in 2023, then tumbled by 96.98% to $600000.0 in 2024, then skyrocketed by 400.0% to $3.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Intangibles were $3.0 million in Q4 2025, $7.4 million in Q3 2025, and $900000.0 in Q2 2025.